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Chapter 11
An International Perspective 
on the Regulation of Rodenticides
John D. Eisemann, Penny M. Fisher, Alan Buckle, and Simon Humphrys
1  Introduction
In the late 1940s, anticoagulant active ingredients were introduced into the global 
rodenticide market. They were rapidly favored over existing rodenticides, such as 
red squill, zinc phosphide, strychnine and inorganic compounds, because they were 
comparatively inexpensive and did not appear to have any unpalatable taste, odor or 
cause any immediate post-ingestive reaction that could lead to bait shyness in rodents 
(Wardrop and Keeling 2008). The number of products registered in the United States 
(US) under Section 3 of the Federal Fungicide, Insecticide and Rodenticide Act 
(FIFRA), which was passed in 1947 and was the first US law to require product 
registration, illustrates the rapid dominance of anticoagulants in the US rodenticide 
market (Fig. 11.1). It is striking that the number of anticoagulant- based rodenticide 
products (ARs) registered under FIFRA was more than two times greater than the 
other categories of rodenticide active ingredients 40 years after the enactment of 
FIFRA.  The greatest number of rodenticide products registered in a single year 
under Section 3 of FIFRA (750) was in 1985, and ARs accounted for 547 (73%) of 
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those products. Similar data for international markets is difficult to collate, but it is 
expected that this rapid rise in popularity was paralleled around the world.
The evolution of pesticide regulations throughout the world followed many dif-
ferent paths. In some countries, including the US and Australia (AUS), the path to 
current regulatory paradigms appears to have been built on expanding the scope of 
legislation originally enacted to protect consumers from fraudulent products, but 
has since evolved to include multiple layers of human health and environmental 
protections demanded by an increasingly vocal public. US pesticide regulations are 
based on two principal acts, however, multiple human health and safety, and envi-
ronmental laws also influence the conditions under which a product will be approved 
and ultimately used. Like in the US and AUS, New Zealand’s (NZ) road to regula-
tion appears to have been based on a single pesticide law. However, they appear to 
have attempted to combine multiple and sometimes conflicting regulations aimed at 
human and environmental protection into one umbrella act, which now governs the 
use of all hazardous substances, including rodenticides. The most dramatic change 
in international pesticide regulation is currently being undertaken in the European 
Union (EU), where a massive attempt is being made to consolidate pesticide regula-
tion across individual European Member States into one harmonized set of regula-
tions, agreed upon by all members. This consolidation approach to pesticide regulation 
may someday be undertaken on a global scale. However, the difficulties currently 
being encountered within the EU from this harmonization effort do not bode well for 
future larger scale adoption on any foreseeable time scale. One  common thread 
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Fig. 11.1 Number of rodenticide products registered in the US since passage of the Federal 
Insecticide, Fungicide and Rodenticide Act (FIFRA)  in 1947. Data presented is only for rodenti-
cide products registered under FIFRA Section 3 and does not include aluminum or magnesium 
phosphide, gas cartridges thallium sulfate, or white phosphorous (NPIRS 2014)
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throughout the international pesticide regulatory environments is that pesticide 
laws appear to be based on a risk-benefit paradigm, and if products have significant 
economic (not necessarily just for manufacturers) and social benefit, products can 
be approved for use despite other potential or known risks. To achieve this result, 
regulators may impose restrictions on use, typically identified on the product label, 
that mitigate the potential hazards a product presents.
The development of pesticide regulation can have a dramatic impact on the avail-
ability and use of products. Legislation on a national scale sets the standards for all 
subsequent regulatory activities, and these broad laws can have a major impact on 
product availability. Another influence, perhaps equally impactful, can be the inter-
pretation of the intent of legislation by regulators charged with enforcing federal 
and sometimes state regulations. The rules, guidelines and processes enacted by the 
regulatory authorities significantly influence the types of products allowed on the 
market, the speed and cost of registering products, and the motivation of private 
industry to seek safer uses of ARs or new rodenticide formulations.
Inferences can be drawn as to the impact of regulations by examining the number 
of products being brought into or removed from the market. Trends in product reg-
istrations in the US illustrate major shifts in product availability (NPIRS 2014). 
Some of these shifts appear to be directly the result of significant regulatory change. 
For example, the rodenticide product availability in the US grew rapidly between 
1950 and 1990 (Fig. 11.1). However, beginning in 1989, the number of rodenticide 
products in the US market began plummeting from the high of 750, to the roughly 
300 products on the market today. What happened in the US in the late 1980s that 
caused this dramatic decrease in product availability?
This chapter examines the historical influences that shaped the current regulatory 
environment around rodenticides in US, NZ, EU, and AUS. It compares and con-
trasts how products are registered, what forces shaped regulatory decisions, and 
speculates on the future trends in product availability for rodent control over the 
next 25 years. As you will see throughout this chapter, product availability through-
out the world has been influenced greatly by increased scientific understanding of 
rodenticides’ impact on humans and the environment, and the associated increased 
societal demands for safer products and more stringent regulation.
2  Anticoagulant Rodenticde Regulation in the United States
2.1  Legislative Actions
The earliest pesticide legislation in the US was the Insecticide Act of 1910 (P.L. 
61–152, 36 Stat. 331), which was enacted primarily to protect consumers from 
fraudulent products. Today, there are numerous US federal laws that regulate the use 
of pesticides, however, two Acts form the primary framework for pesticide regula-
tion, the Federal Food, Drug and Cosmetic Act (FFDCA), originally enacted in 
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1938 [P.L. 75–717, 52 Stat 1040], and the Federal Insecticide, Fungicide and 
Rodenticide Act (FIFRA) of 1947 [P.L. 80–104, 61 Stat. 163]. FIFRA ushered in 
landmark changes to pesticide regulation, two of the most significant being a 
requirement for standardized label language and that all products be registered with 
the US Department of Agriculture (USDA) prior to interstate or international ship-
ment. These two actions established the foundation of today’s regulatory environ-
ment by centralizing regulatory review under one agency and providing consumers 
a means to identify the manufacturer and purity of the product they were purchas-
ing. Since that time, these laws have been amended numerous times and new laws 
have been enacted to keep pace with cultural changes and increased scientific 
understanding of pesticide chemistry. They now include regulatory considerations 
for protecting human health and providing safety from direct and indirect exposure, 
special protections for children, limits on the amount of residues allowed in food, 
and a wide variety of environmental protections.
Prior to the 1970s, pesticides were regulated by the USDA, and the general tenor 
of the regulations favored agribusiness (Carson 1962). However, an increasing seg-
ment of US society considered pesticides to be under-regulated. There was growing 
fear that FIFRA and the FFDCA failed to provide adequate guidance on the proper 
use of pesticide products, and that insufficient data were required of manufacturers 
to support product registrations (Carson 1962). Consequently, many felt it was 
impossible for regulators to assess the potential human and environmental risks 
associated with pesticide use. Arguably the foremost publication that galvanized 
public sentiment against what was perceived to be an over-promoted and under- 
regulated pesticide industry was Rachael Carson’s ‘Silent Spring’ (Carson 1962). 
Silent Spring served as a rallying call for splintered concern over unknown pesticide 
impacts and spurred private citizens and public interest groups to mount political 
pressure for pesticide reform (Bosso 1988). The first Earth Day in the US occurred 
in 1969. In 1970, President Richard Nixon established the US Environmental 
Protection Agency (US EPA, 35FR 15623, 84 Stat. 2086) and at the same time, 
transferred regulatory oversight of pesticides from the USDA to the US EPA.
Two major legislative actions occurred in 1972, the Congress amended the pre-
decessor to the Endangered Species Act (P.L. 93–205, December 28, 1987, 87 Stat. 
903) to define imminent hazard to include situations involving unreasonable hazard 
due to the survival of a threatened or endangered species, including pesticides and 
Congress amended FIFRA with the passage of the Federal Environmental Pesticide 
Control Act (FEPCA, P.L. 92–516, October 21, 1972, 86 Stat. 973). The FEPCA 
included four actions that significantly impacted the use of pesticides. First, it 
required a systematic review of pesticide labels and supporting data for all products 
registered with the US EPA. Second, it established the risk standard of ‘unreason-
able adverse effects’ defined it as ‘any unreasonable risk to man or the environment, 
taking into account the economic, social, and environmental costs and benefits of 
the use of a pesticide.’ Third, the Act mandated that, in addition to US EPA evaluat-
ing the risk to human health and the environment posed by pesticide product, US 
EPA must also consider the benefits of continued use, primarily economic benefits. 
Finally, the Act also established a dual classification system for pesticide products, 
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General Use and Restricted Use. General Use products were those found to be safe 
when used according to label directions and could be sold to general consumers. 
Restricted Use products are those found to have a higher potential for risk when 
used according to label directions, and would only be available to trained certified 
applicators.
US EPA faced a daunting task under the FEPCA. At the time the law was passed, 
US EPA oversaw product registrations that included hundreds of active ingredients 
and thousands of end-use-products and associated degradates. The US EPA was 
required to implement all aspects of the FEPCA for all existing and new products 
within 4 years of passage. By the mid-1970s, EPA began releasing ‘Registration 
Standards’ which summarized the available data supporting a product registration 
and, if necessary, required additional data be submitted. These data were used to 
conduct human health and environmental assessments to assess the potential risk 
when pesticide products were used in accordance with label directions. When label 
directions were assumed to lead to unreasonable adverse effect(s), product use was 
restricted by modifying label language and/or additional data was required to fur-
ther understand the potential risk. Registration Standards for rodenticide products 
began to be issued in 1981 for the first active ingredient, warfarin.
The next major revision to US pesticide laws came in the form of amendments to 
FIFRA in 1988 (P.L. 100–532, October 25, 1988, 102 Stat. 2655). These changes 
were prompted in part because of the slow progress US EPA was making in product 
reviews under the FEPCA. The principal changes to FIFRA were the standardiza-
tion of chemical review methods and concurrent implementing process in which 
registrants were required to identify and commit to submitting missing or additional 
data required by EPA. This process culminated in US EPA’s comprehensive exami-
nation of product label language and data submitted in support of continued product 
registration or ‘re-registration,’ and issuance of Registration Eligibility Decisions 
(REDs). With renewed emphasis on the speed and comprehensiveness of regulatory 
review, the US EPA required registrants to submit thousands of missing or invalid 
studies on pesticide active ingredients, degradates, and end-use products. Because 
of the significant financial investment required to keep products on the market and 
pressure on US EPA to restrict or eliminate the use of the most hazardous products, 
the number of pesticide registrations began to decline. As observed by the product 
registration trend lines in Fig. 11.1, the 1988 amendments to FIFRA had significant 
impacts on the availability of all rodenticide products. At the peak of the US roden-
ticide market in 1985, 750 rodenticide products were registered with the US EPA. 
By 1994, the number of rodenticide products had plummeted to about one- half of 
that number.
The dramatic decline in product registrations was not primarily due to US EPA’s 
determination that the products were too hazardous to be registered. Rather, most 
products were voluntarily or passively cancelled because registrants declined to pay 
the registration fees or cost necessary to maintain the registration (Jacobs 1992). 
According to Jacobs (1992), between 1989 and 1991, 52% of all pesticide products 
(not limited to rodenticides) registered under FIFRA Section 3 were cancelled due to 
registrant’s failure to pay the increased annual registration maintenance fees imple-
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mented by the 1988 amendments to FIFRA. While Jacobs (1992) does assign a dol-
lar value to the cost associated with the 1986 US EPA Data Call-In and 1988 
amendments to FIFRA, it is speculated that this increased cost to keep low value 
pesticides on the market contributed to a dramatic increase in product cancellations.
While there have been other amendments to FIFRA and the FFDCA since 1988, 
the legislation that most significantly impacted human health and safety issues 
related to pesticide use was the Food Quality Protection Act (FQPA) of 1996 (P.L. 
104–170, August 3, 1996), which amended the FFDCA and FIFRA. FQPA regula-
tions covered all pesticides, including rodenticides, but because there are few roden-
ticide food or feed uses, the impact was not as large as on conventional agricultural 
pesticides.
2.2  Legislation Implementation Actions
Laws passed by the US Congress form the regulatory framework for pesticide mar-
kets and those laws can have wide ranging impacts. However, in many instances, the 
implementation processes established by regulatory authorities, or judicial interpre-
tation of the laws or implementation processes, can have an even more dramatic 
impact of the availability and use of pesticide products. A perfect example of this 
can be observed by examining the regulatory history of strychnine-based products. 
Insights into the future of ARs can be drawn from this case study.
Strychnine: A case study in the non-legislative impacts on product availability in 
the US
In 1947, the year FIFRA was enacted and product registrations were required, 
strychnine-based products accounted for 85% of all rodenticide products registered 
with the USDA. Today they account for less than 10% of the US rodenticide market 
(Fig.  11.2). The demise of strychnine can be attributed to increased competition 
from other rodenticide active ingredients, including the introduction of ARs, but 
also to mounting evidence of significant negative impacts on non-target species, 
sustained vocal public opposition to continued use, and the response of regulatory 
and non-regulatory bodies.
A growing concern for non-target hazards posed by above-ground uses prompted 
President Richard M. Nixon to issue an Executive Order (Executive Order 11643) 
prohibiting the use of all toxicants, including strychnine, for controlling predatory 
mammals and birds on federal lands or in federal programs. By 1976, US EPA’s 
technical review of the supporting data and consideration of input of concerned par-
ties resulted in a determination that strychnine presented unacceptable risk to appli-
cators and non-target species, and they issued a notice on the Rebuttable Presumption 
Against Registration (RPAR) against all outdoor, above-ground uses of strychnine 
products (41 FR 52810, December 1, 1976). By 1983, US EPA published a notice 
of its intent to restrict all strychnine products to a maximum concentration of 0.5%, 
and to cancel registration of strychnine for above-ground use against most target 
species, including prairie dogs and meadow mice (48 FR 48523, October 19, 1983).
J.D. Eisemann et al.
293
Following EPA’s 1983 announcement, a series of judicial challenges were filed 
on behalf of agricultural and environmental interests, including among others the 
Wyoming Department of Agriculture, Defenders of Wildlife, and Sierra Club (Wade 
1985; Defenders of Wildlife 1988). In 1988, the US Circuit Court in Minnesota 
issued an injunction against all above-ground uses of strychnine to protect non- 
target species (Defenders of Wildlife 1988). To this date, US EPA has not approached 
the US Circuit Court with proposals to modify the injunction against above-ground 
uses of strychnine, and all current uses of strychnine products are limited to below- 
ground applications to manage pocket gophers.
Most recently, in December 2009, the State FIFRA Research and Evaluation 
Group (SFIREG), a group composed of representatives from State pesticide regula-
tory authorities, petitioned US EPA to reclassify all strychnine products as Restricted 
Use products (US EPA 2009). At the time of writing this chapter, all of the responses 
to US EPA’s request for comments supported the petitioner’s request, but the US 
EPA has not publically acted on this petition. However, US EPA has recently begun 
another review, ‘Registration Review,’ and published a final work plan in June 2016 
(US EPA, 2016b). It is possible US EPA is withholding any action on this petition 
until they complete their re-evaluation in 2021.
The legislative regulatory path of strychnine was not unlike all other pesticides 
regulated by the US EPA under FIFRA and the FFDCA. The decrease in the market 
share of strychnine products from 1988 to 1996 (Fig. 11.2) can be linked to the 1988 
injunction levied by the US District Court in Minnesota against above-ground uses 
to control rodents, but also to the impact of the legislatively-required periodic 
review of pesticide products and associated data requirements. The regulatory his-
tory of strychnine may serve as a harbinger of the future of ARs. Second generation 
anticoagulant rodenticides (SGARs) have not been proposed for cancellation by the 
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Fig. 11.2 Percent of rodenticide products registered under FIFRA that contain strychnine, other 
acute toxicants, and anticoagulant active ingredients since 1947 (NPIRS 2014)
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US EPA. However, mounting evidence of non-target impacts and the constant 
public pressure against their continued use may ultimately lead to a shrinking role 
for them in the future rodenticide market.
2.3  Regulatory Implementation Actions on Anticoagulant 
Rodenticides
In 1947, US EPA began an aggregate risk and benefit analysis of common AR prod-
ucts in the 1990s. They published their analysis in the Registration Eligibility 
Decision (RED), Rodenticide Cluster (US EPA 1998). US EPA concluded that all 
uses of brodifacoum, bromethalin (not an AR), and bromadiolone were eligible for 
registration. Chlorophacinone and diphacinone and its sodium salt, were also suit-
able for registration, with the exception of some field uses. Pival was ineligible for 
re-registration because the registrant failed to respond to the Agency’s Data Call-in 
Notice.
For products remaining on the market, US EPA began a two-phase approach to 
mitigating environmental and human health impacts. Phase One included short- 
term mitigation measures such as classification of all tracking powders and field use 
products as Restricted Use Pesticides, the addition of an indicator dye (later aban-
doned), new labeling requirements designed to clarify proper placement in and 
around buildings, and registrants were required to submit annual summaries of acci-
dental poisonings compiled by the American Association of Poison Control Centers. 
Phase Two was aimed at longer-term risk mitigation measures primarily focused on 
prompting the rodenticide industry to develop safer application technologies.
While these proposed mitigation measures were playing out between US EPA 
and industry, US EPA began an in-depth environmental risk assessment of nine 
active ingredients used in rodenticide products and published their findings in 2004 
(Erickson and Urban 2004). This risk assessment advanced US EPA’s standard sto-
chastic risk assessment methods to include probabilistic risk assessment techniques. 
They identified that products containing brodifacoum, difethialone, and zinc phos-
phide presented the greatest overall hazard to birds and non-target wildlife. In addi-
tion, baits formulated with loose grains presented the highest ecological hazard.
In 2008, EPA published a final decision on risk mitigation measures for rodenti-
cide products intended to reduce the potential of accidental exposure in children, 
companion animals, and environmental risk (Table 11.1, US EPA 2008). The roden-
ticide industry was given 3 years to comply. Most product manufacturers responded 
by voluntarily cancelling less profitable products and changing other product for-
mulations and use patterns to comply with the new guidelines. The few registrants 
who initially challenged US EPA’s authority to implement these measures finally 
complied in 2014 (US EPA 2014). The impact of these mitigation measures can be 
observed in the slight drop in the number of products containing SGARs beginning 
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in 2008, and a slight increase in the number of registrations of products containing 
acute toxicants (Fig. 11.3).
In the US, State governments have the right under FIFRA to enact rules and regu-
lations that further restrict the use of pesticide products within their State. California 
exercised that right in 2014 in an effort to address a state-wide problem of wildlife 
exposure and poisoning from products containing SGARs. Assembly Bill No. 2657 
prohibits the use of brodifacoum, bromadiolone, difenacoum, and difethialone in 
‘wildlife habitat areas’, including state parks, state wildlife management areas, or 
state conservancy areas. In 2016, Assembly Bill 2596, a far more sweeping prohibi-
tion on the use of rodenticides, was introduced into the California Legislature. If 
passed as proposed, the California Natural Predator Protection Act of 2016 (pro-
posed name) would read as follows ‘…the use of any pesticide that contains one or 
more of the following anticoagulants is prohibited in this state: brodifacoum, bro-
madiolone, chlorophacinone, cholecalciferol (not an AR), difenacoum, difethialone, 
Table 11.1 Rodenticide risk mitigation measures enacted by US EPA (US EPA 2008)
To reduce risk to children To reduce risk to non-target birds and Mammals
All “consumer size” rodenticide bait 
products must be sold packaged together 
with a ready-to-use (prebaited) bait station. 
Only the active ingredients 
chlorophacinone, diphacinone, warfarin, 
bromethalin, cholecalciferol, and zinc 
phosphide were allowed in consumer sized 
baits. New bait station design and testing 
standards were developed and a 4 tier suite 
of bait stations were identified.
Minimum package size requirements in order to 
minimize the availability of second-generation 
anticoagulant products on the general consumer 
market. Second-generation bait products must be 
sold in packages that contain >8 pounds of bait 
for products that are labeled for use only inside 
of and within 50 ft of agricultural buildings and 
not for use in and around the home. For products 
intended for use by professional applicators, the 
minimum permissible amount of bait per 
package is 16 pounds.
Bait stations may be (1) non-refillable 
(disposable, one-time use stations), or (2) 
refillable (sold with bait refills). Consumer 
size bait stations was limited to a total of 1 
pound of bait (initial load and refill 
combined). Bait refills must be sold with a 
bait station.
Use site restrictions on products containing 
brodifacoum, difethialone, difenacoum, or 
bromadialone. Products containing at least 8 but 
not more than 16 pounds of bait may only be 
used in and around (within 50 ft) of agricultural 
buildings (e.g., barns, hen houses), and bear the 
statement “Do not use this product in homes or 
other human residences.’
Meal, treated whole-grain, pelleted, and 
liquid forms of bait were prohibited except 
in agricultural sites. Bait blocks were the 
only form of bait approved for consumer 
size products.
Sale and distribution restrictions on products 
containing brodifacoum, difethialone, 
difenacoum, or bromadialone such that they can 
only be sold or distributed in agricultural stores 
or to Pest Control Operators.
Below ground uses were excluded from bait 
station and bait block requirements.
Bait station required for outdoor above-ground 
placements of second generation anticoagulants. 
Tamper resistant bait stations are required if the 
placement is within reach of pets, domestic 
animals, non-target wildlife, or children under 
6 years of age.
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diphacinone, warfarin.’ Both California bills exempt agricultural uses of ARs from 
the prohibitions.
In 2016, US EPA announced their efforts to develop a new web-based system, 
Bulletins Live 2, which will provide pesticide applicators with guidance on whether 
the proposed pesticide use is prohibited spatially or temporally because of potential 
risk to threatened and endangered species (T&E) (US EPA 2016a). Working in con-
junction with the U.S. Fish and Wildlife Service, Endangered Species Office, this 
system will have the benefit of providing species range maps at the township level, 
perhaps allowing applications in counties where they might have been previously 
prohibited because previous maps were based on county-level species occurrence. 
This system might also further to restrict pesticide applications because the ability 
to respond to changes in known species ranges is much quicker than the old system 
requiring T&E species prohibitions listed on individual labels. Despite EPA’s cur-
rent efforts, the benefits of this system on a wide-scale will not be realized for years 
into the future. There are only a limited number of bulletins currently available on 
the EPA website  (https://www.epa.gov/endangered-species/endangered-species- 
protection-bulletins).
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3  Anticoagulant Rodenticide Regulation in New Zealand
3.1  The Agricultural Compounds and Veterinary Medicine  
Act 1997
Currently, seven AR compounds are registered in NZ as the active ingredient in 
formulations classed as ‘vertebrate toxic agents’ (VTAs). A VTA is a subset of 
‘agricultural compounds’ as defined under the Agricultural Compounds and 
Veterinary Medicines (ACVM) Act 1997 (Public Act 1997 No. 87). The Approvals 
and ACVM Group sits within the Ministry for Primary Industries and is responsible 
for developing, implementing and confirming compliance to the NZ approval pro-
cesses under the ACVM Act, alongside other legislation and amendments. The pur-
pose of the ACVM Act is to prevent or manage risks associated with the use of 
VTAs, including risks in trade of agricultural produce, public health, animal welfare 
and agricultural security. In addition, the Act is to ensure that there are no breaches 
in domestic food residue standards and that there is provision of sufficient consumer 
information about the VTA products.
Formulations of VTAs are generally trade name products used to kill, control, or 
limit the viability of vertebrate pests. All VTAs imported, manufactured, sold or 
used in NZ must be authorized under the ACVM Act and Regulations, under one of 
three types of authorization: (i) registration of a specific trade name product under 
section 21 of the ACVM Act, which is essentially an approval to promote, advertise, 
or sell a VTA, (ii) provisional registration to undertake research to obtain informa-
tion to determine whether a VTA should be registered, and (iii) approval in special 
circumstances to allow conditional VTA use without registration or provisional 
registration.
The New Zealand Ministry for Primary Industries (MPI) is responsible for regis-
tration of VTAs, which undergo a technical appraisal and risk assessment of their 
quality, humaneness (relating to animal welfare) and efficacy. During registration, 
MPI determines which of three categories apply to a VTA: (i) unrestricted sale and 
unrestricted use, (ii) restricted sale and unrestricted use, or (iii) restricted sale and 
restricted use. Unrestricted sale and use VTA products (over-the-counter or OTC) 
have no restriction on their sale, no expectation of trace-back through the wholesale 
or retail trade, and no notification or signage requirements around their use. They 
may be promoted in ways to ensure that potential users are properly informed about 
the products and used within the conditions of registration. Generally this category 
includes poisons used in small quantities for domestic, non-commercial pest control 
and includes a range of first generation AR (FGAR) and SGAR actives. Table 11.2 
summarizes the number of products containing ARs as the active agent currently 
registered in NZ, which includes both restricted and unrestricted products.
The ‘restricted sale, unrestricted use’ VTA product category requires additional 
instruction or advice (over and above the label information) at the point-of-sale to 
ensure that they are used appropriately, which may also entail additional recording 
of distribution or sales. This group includes some products used for commercial pest 
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control that can be sold only by persons approved by the ACVM Group. They may 
be required to maintain records of sale, particularly if it is considered necessary to 
have a trace-back capability. Users purchasing such products do not have to be 
approved. ‘Restricted sale and use’ VTA products have conditions on both sellers 
and users, whereby both parties need to be approved by the ACVM Group. Restricted 
sale and use VTA trade name products must not be promoted or advertised.
3.2  The Hazardous Substances and New Organisms Act 2001
The development of the Hazardous Substances and New Organisms Act 1996 (the 
HSNO Act) began in 1988 when the Interagency Co-ordinating Committee on 
Pollution and Hazardous Substances recommended that a new legislative frame-
work for controlling hazardous substances be developed. Previously, chemical and 
biological products in NZ were regulated under a range of legislation (Thompson 
1973). Each piece of legislation was directed towards a particular product type or 
aspect of its use, e.g. the Pesticides Act 1979, the Animal Remedies Act 1967, the 
Toxic Substances Act 1979, the Explosives Act 1957, the Plants Act 1970, and the 
Dangerous Goods Act 1974. One critique was that these statutes were often incon-
sistent and required implementation by a range of agencies with different regulatory 
missions (Allen and Clark 2006). In order to implement a more streamlined, better- 
practice approach to managing hazardous substances, a “One Act, One Authority” 
model was agreed upon. The HSNO Act consolidated existing legislation, and the 
Ministry for the Environment was charged with administering the legislation with 
support from the newly formed Environmental Risk Management Authority NZ and 
its operational agency (ERMA NZ). This agency was disestablished on June 30, 
2011, and its functions were incorporated into the NZ Environmental Protection 
Agency (NZ EPA).
Table 11.2 Anticoagulant compounds that are active agents in currently-registered vertebrate 
toxic agent formulations, available as products in NZ as of 2016 (MPI 2016).
Anticoagulant Active Ingredient
Number of 
products
First year a product 
was registered
Most recent year a 
product was registered
Brodifacoum SGARa 20 1996 2016
Bromadiolone SGAR 6 1981 2013
Coumatetralyl SGAR 3 1980 1999
Difethialone SGAR 3 2013 2014
Diphacinone FGARb 8 1984 2015
Flocoumafen SGAR 1 2003 2003
Pindone FGAR 4 1992 2001
TOTAL 45
aSecond Generation Anticoagulant
bFirst Generation Anticoagulant
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The HSNO Act reformed the way that hazardous substances are dealt with in 
NZ. As part of the consolidation process, all existing hazardous substances were 
transferred from the multiple-legislation regime. In 1997, the NZ Pesticide Board 
was still operational (Eason et al. 1997) and considering criteria for reassessment of 
VTAs registered before 1980 (e.g., sodium fluoroacetate, cyanide, phosphorus, pin-
done). After a series of transitional provisions to allow for the continued manufac-
ture and importation of products that were legally used in NZ before commencement 
of new legislation, the HSNO Act came into full effect on July 2, 2001. The HSNO 
Act aims to prevent, mitigate or otherwise manage the adverse effects that hazard-
ous substances and new organisms pose to the health and safety of people and envi-
ronmental health, by managing the substances throughout their life cycle (i.e., in 
respect to manufacture, importation, sale, use and disposal in NZ). A product 
requires approval under the HSNO Act if it is a substance with one or more hazard-
ous properties that exceeds a prescribed threshold. The definition of substance in 
this legislation is broad and covers mixtures of chemical and biological compounds 
such as household detergents, industrial reagents, and agricultural compounds  – 
including ARs and their formulations in bait.
For a substance without a pre-existing approval, the HSNO Act places the onus 
on the manufacturer or importer to provide sufficient data describing the hazardous 
properties of their product. It is on this information that a determination is based, as 
to whether or not a product is hazardous and therefore, requires approval. Once a 
product is approved, any manufacturer or importer may rely on that approval; an 
exception to this general rule is where the product is also an innovative agricultural 
compound or medicine, and this could include some anticoagulant VTAs. Although 
applicants may identify information submitted in support of an approval application 
as being confidential, situations may arise where this information can be released to 
the public.
Section 140 of the HSNO Act provides for regulations to be made to support the 
implementation of the Act. The most relevant regulations are general sets of regula-
tions that outline the skills and knowledge required to hold office under the HSNO 
Act, and regulations that classify hazardous substances and set out control mecha-
nisms that must be applied when dealing with these. Other sets of regulations relate 
to the information requirements that must be used (i.e., labelling, packaging, sig-
nage, advertising, documentation and tracking requirements).
Section 78 of the HSNO Act enables the Environmental Protection Agency New 
Zealand (EPA NZ, previously ERMA) to issue, amend, approve, or revoke an 
approved code of practice (ACOP) regarding the control of a hazardous substance. 
This section also gives EPA NZ the ability to approve codes of practice developed 
by other people if it considers these to be acceptable.
Section 79 of the Act sets out the consultation and notification process that must 
be undertaken as part of the approval process whereby a HSNO ACOP provides a 
mechanism to assist people to achieve compliance with the controls set out in the 
legislation. In the case of ARs, a code of practice has been developed for the broad-
cast application of a particular formulation of brodifacoum bait for rodent eradica-
tion (Anonymous 2006).
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3.3  Anticoagulant Rodenticide Use in New Zealand
As of June 1972, there were 1126 fully registered and 180 provisionally registered 
products containing agricultural chemicals, of which 11 were classified as rodenti-
cides (Thompson 1973). Warfarin was historically used in NZ for rodent control, 
with at least two commercial bait formulations registered by the Pesticides Board, 
but these registrations apparently lapsed in June 2000.
There is no formal reporting information publically available regarding the 
annual retail sales and quantities of some ARs used for commensal rodent control. 
Therefore, it is difficult to determine the overall and proportional uses for commen-
sal control by (i) the general public who purchase ARs through various retail outlets, 
(ii) owners or managers of businesses where there is a formal regulatory mandate 
for rodent control, or (iii) professional pest control companies that are contracted by 
private individuals or businesses to undertake rodent control in and around 
buildings.
All currently-registered ARs in NZ (Table 11.2)  target Rattus norvegicus, R. rat-
tus, R. exulans and/or Mus musculus, however, brodifacoum formulations are cur-
rently also used for brushtail possum (Trichosurus vulpecula) management, and 
pindone formulations for possum and rabbit (Oryctolagus cuniculus) management. 
Neither chlorophacinone nor difenacoum appears to have yet been registered in 
NZ.  In contrast to the USA and EU, there have not been any recent significant 
changes to the ways in which ARs are registered or regulated in NZ. However, per-
haps in response to increased restriction and decreased markets for SGAR products 
in other places, in the last 4–5 years, there has been a marked flurry of new registra-
tions (Fig. 11.4), such that there are now more products containing SGARs than 
ever before ‘on the books’ in NZ .
There are two broad use patterns for ARs in NZ: the control of rodents (rats and/
or mice) living commensally with human habitation (“commensal control”) and 
field application for management of populations of targeted pests (rodents, pos-
sums, rabbits). Commensal control is where bait is applied in and around buildings 
or structures that can harbor rodents including residential households, farm build-
ings, factories, warehouses, commercial food handling premises, and on boats. The 
use of over-the-counter ARs, alongside trapping, are probably the most commonly 
used method for commensal rodent control in NZ, and a variety of bait formulations 
containing SGARs are widely retailed to general public.
The second broad use pattern of ARs is for ‘field control’ of pest animals. ARs 
are generally not applied for arable crop protection in NZ, however, a globally dis-
tinctive use pattern covers control of pest animals living in situations removed from 
human habitation (“field control”), which can include bush/pasture margins, for-
ested areas, dune/coastal areas, conservation estate and offshore islands. Almost 
exclusively, these aim to protect biodiversity values from the impacts of rats, and 
other introduced mammals, as predators or competitors of native NZ fauna and 
flora. They are also to manage possum populations as wildlife vectors of bovine 
tuberculosis. Perhaps the most notable NZ field use pattern is aerial broadcast 
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 application of brodifacoum for control of rodents on non-stocked offshore islands or 
mainland areas enclosed by an effective pest-proof fence. This usage is strictly lim-
ited to the Department of Conservation and authorised persons, subject to a formal 
Code of Practice (Anonymous 2006). While this is not a frequent use, applications 
can be on a very large scale to facilitate the eradication of rodents from offshore 
islands where reinvasion can be prevented (Fisher et al. 2011).
4  Regulation of Anticoagulant Rodenticides in the European 
Union
Anticoagulant rodenticides are widely used in the EU for rodent pest management. 
The sale and use of ARs in the EU is regulated under two different legal instru-
ments. Those applied to growing crops are known as ‘pesticides’ and are subject to 
regulation under the Plant Protection Products Directive (European Council 1991), 
and the subsequent implementing Regulation (European Council 2009). Those 
applied for all other uses, considered to be biocides, are regulated under different 
legislation, the Biocidal Products Directive, and known as the BPD (European 
Community 1988). Having two different regulatory procedures for the same 
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Fig. 11.4 Numbers of currently registered vertebrate toxic agents in New Zealand containing 
anticoagulants as actives, showing which year these products were first registered. Does not show 
discontinued or deregistered vertebrate pesticides (MPI 2016)
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substances necessitated a clear dividing line between them to prevent duplication of 
effort. After considerable consultation and deliberation, the European Commission 
(the Commission) made this dividing line the ‘field gate’. In other words, if ARs are 
used to protect any crop ‘in field’, whether the crop is actually growing or stored 
(e.g., clamps of root vegetables), such uses are considered to be pesticides for crop 
protection. Any ARs applied beyond the field, and such uses are extremely varied 
but include the storage of processed agricultural produce within farm buildings, are 
considered biocides (European Commission 2005, 2015).
Applications of ARs in Europe for plant protection are relatively few. There are 
several reasons for this. Firstly, rodent pest pressure in European agricultural is 
somewhat limited, although of course, rodent pest damage to a range of agricultural 
and forestry crops is well-documented, especially in southern European countries 
with warmer climates (Buckle and Pelz 2015). The second and probably more 
important reason for the restricted use of ARs in European crop protection is that 
mitigation measures are largely unavailable to prevent environmental impacts in 
these uses (see Chap. 12). The balance between risk and benefit is therefore tilted 
significantly against such applications when product authorisations are considered 
by regulators. Hence, by far the greatest quantities of ARs are applied in the EU as 
biocides to protect human and animal health. The remainder of this section will deal 
mainly with regulation of such uses.
4.1  The Biocidal Products Directive and Regulation
Until the development and implementation of the EU’s BPD (European Community 
1998), the regulation of ARs in Europe was conducted through a series of national 
statutes and other country-specific legal regulatory instruments. In some countries, 
such as the UK where the Control of Pesticides Regulation (1986) (COPR) as 
amended (1997) was in force (Health and Safety Executive 2016), anticoagulants 
were fully regulated according to strict UK national requirements. In other European 
countries, Germany for instance, there was little or no formal regulation of rodenti-
cides. This situation underwent fundamental change with the introduction of the 
BPD, and with the subsequent implementing Regulation, the Biocidal Products 
Regulation (BPR) (European Union 2012). This regulation encompasses ARs, and 
a wide range of other common biocides such as insecticides, disinfectants, wood 
preservatives, and anti-fouling agents, as well as less some less widely-used chemi-
cals, such as embalming fluids, metal-working fluid preservatives, piscicides, and 
others (Knight and Cook 2002).
One of the principal objectives of the EU is to promote free flow of products and 
services between Member States (MSs), without the imposition of unnecessary 
regulatory barriers. Clearly, in terms of the movement and use of ARs across Europe, 
this requires a common framework of regulation of use practices, product registra-
tions (termed authorisations in the EU) and product labelling. The BPD was devel-
oped to provide this framework for chemical biocides. The main, and highly 
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laudable, regulatory principle of the BPD was to implement the highest possible 
standards of protection of human health and the environment (European Community 
1998). This is explicit in the eighth of the ‘whereas’ clauses that conventionally 
precede all EU Directives, as follows:
Whereas it is necessary, when biocidal products are being authorised, to make sure that, 
when properly used for the purpose intended, they are sufficiently effective and have no 
unacceptable effect on the target organisms such as resistance or unacceptable tolerance, 
and, in the case of vertebrate animals, unnecessary suffering and pain, and have, in the 
light of current scientific and technical knowledge, no unacceptable effect on the environ-
ment and, in particular, on human or animal health;
It is apparent from other chapters in this book that all of the issues raised in this 
clause, including resistance, humaneness, and non-target impacts, are relevant con-
siderations in the regulation of the ARs in Europe and elsewhere.
The aims of the European regulators who framed this Directive are supported by 
everybody, including country authorities, manufacturers, and users, but the vast cost 
of delivering them has been almost exclusively borne by the industry that develops 
and puts ARs and other biocides onto the European market (Buckle 2002). These 
costs (see Adams 2005) have had a stifling effect on research and innovation, 
because funds which would have supported new product development have been 
diverted for two decades into projects aimed at keeping old ones on the market. A 
key benefit of the BPD/BPR presented to industry, and one keenly sought by the 
Commission, was reduced regulatory costs resulting from harmonized regulation 
across the EU. In other words, similar (or even the same) products having the same 
use patterns and risks, being regulated in a similar way among all EU countries. 
This benefit has remained almost entirely unrealized because of a failure to agree 
common regulatory principles affecting ARs among the Member States of the EU 
(see examples below).
4.2  Operation of the Biocidal Products Directive
The Commission, the executive body of the European Parliament and Union, is the 
agency which proposed legislation for regulating biocides and is now charged with 
implementing decisions of the Parliament in respect of the BPR. However, as with 
many other European regulatory schemes, implementation ‘on the ground’ is multi- 
layered and another organization, the European Chemicals Agency (ECHA), man-
ages the technical, scientific and administrative aspects of implementation. It does 
this by providing guidance to, and in consultation with, MS regulatory authorities, 
which are called ‘Competent Authorities’ (CAs). This European system of regula-
tion of biocides was preceded by the implementation of a system with similar aims 
for the regulation of crop protection chemicals. Therefore, in many respects, the 
operation of the BPD/BPR is similar to the operation of the Plant Protection Products 
Directive (PPPD)/Plant Protection Products Regulation (PPPR) which preceded it.
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Regulatory permission to place a biocidal product on the market in the EU is 
conducted in two stages. In the first, the properties of active substances and the risks 
of their applications are assessed. This is done by the presentation to the Commission, 
by a manufacturer of an active substance, of a dossier of studies that addresses a 
required list of chemical, toxicological, and environmental ‘end points’, which are 
set out at Annex II of the BPR (European Union 2012). The method of dossier sub-
mission is via an electronic portal operated through the ECHA website called the 
Register for Biocidal Products (R4BP), now in its third version R4BP3.
The initial assessment of the dossier is conducted by the CA of a Member State 
nominated by ECHA – the evaluating Member State (eMS or eCA). The eMS com-
pletes a draft Assessment Report and publishes its conclusions within a year, which, 
after a permitted 30-day period for comment by the applicant, is submitted to the 
ECHA Biocidal Products Committee (BPC) for peer review. This review provides a 
270-day period for comment and amendment of the eMS’s draft Assessment Report 
and its conclusions by the CAs of all other EU Member States. The final Assessment 
Report is completed by the Biocidal Products committee (BPC) of ECHA and an 
opinion submitted to the Commission for a decision on the approval of the active 
substance. The cost of these procedures, borne by the applicant, vary depending on 
the nature and scope of the dossier and the cost to the manufacturer of the services 
provided by the eMS, but are in the range €100  k to €500  k (~US $113,000 to 
$565,4000) to per active substance, with additional fees payable to ECHA (European 
Union 2013). This process results in the addition of the active substance to the 
Commission’s list of approved active substances.
Article 5 of the BPR makes provision for active substances to be refused approval 
if they possess one or more of the properties listed in it as ‘exclusion criteria’. This 
is the case for the ARs, because they are considered to be both toxic to reproduction 
and are named potential PBTs (persistent, bio-accumulative, and toxic). However, 
provisions exists for the derogation of exclusion if “the active substance is essential 
to prevent or control a serious danger to human health, animal health or the envi-
ronment” or “not approving the active substance would have a disproportionate 
negative impact on society when compared with the risk to human health, animal 
health or the environment arising from the use of the substance.” One or both of 
these derogations are considered to apply to ARs, and they have been approved for 
use throughout the EU. Nevertheless, when such derogations are invoked, active 
substances to which they are applied are named ‘candidates for substitution’. These 
are then approved only for 5 years (instead of the usual ten) and are subject to a 
review process every 5 years, which involves a public consultation. The public con-
sultation on ARs conducted by ECHA at the first renewal of these active substances 
(i.e., 5 years after first approval) has just closed at time of writing. The consultation 
is carried out to determine whether equally effective and safer alternatives to the 
candidates for substitution have become available. As there are none, ECHA has 
come to the conclusion that all AR active substance approvals will be renewed for a 
further 5 years.
A second and different regulatory procedure is applied to the assessment of prod-
ucts containing approved active substances  – with further substantial fees in the 
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region of €100 k (~US $113,000) per biocidal product payable to MS bodies that 
conduct assessments. If an applicant wishes to sell a product in only one MS, an 
application for authorization of the product is made to the MS in question. Once 
again, a dossier of studies elucidating product chemistry, toxicology, and environ-
mental effect is submitted via R4BP3. The assessment must be completed by the 
MS CA within 1 year. A further provision for ‘candidates for substitution’ is applied 
at this point, the procedure of ‘comparative assessment’ (see Article 28 of the BPR). 
In the case of applications for the authorization of products containing active sub-
stances that are candidates for substitution, the MS CA must conduct an assessment 
to determine “If there is already an authorised product, which is sufficiently effec-
tive, presents no other significant economic or practical disadvantages and does not 
affect the occurrence of resistance in the target organism, the new product will be 
restricted or prohibited.” Once again, these provisions, of course, apply to ARs. 
Comparative assessment (European Commission 2016a) is a new and as yet, 
untested regulatory procedure, and there is much uncertainty about how it is to be 
implemented by the Commission and MSs. It seems to be a global regulatory ‘first’, 
wherein a product is considered by regulators to be both effective and safe, and with 
a full supporting dossier of regulatory studies obtained by a manufacturer at consid-
erable cost, is denied access to the market because an assessment is made that an 
alternative is equally effective and safer. Both of these concepts are notoriously 
difficult to quantify with precision, and the provision for comparative assessment 
seems ripe for legal challenge.
Application for product authorization in only one EU MS is rare. This is because 
it is an important purpose of the BPR is to expedite movement of products through-
out the EU and to harmonize the regulation of ARs among MSs, thereby, reducing 
costs for manufacturers and users. The procedure of ‘mutual recognition’ is intended 
to facilitate this process. In this mechanism, an initial application is made to a single 
MS, called the reference Member State (rMS), which conducts an initial assessment 
of the submitted product regulatory dossier. When the rMS has granted an authori-
zation, the applicant notifies the CAs of all other MSs (called concerned Member 
States, cMS) where authorizations are required. These cMSs must either grant or 
deny authorization within 5 months, without the need for any detailed examination 
of the product dossier. If one or more cMS is not prepared to issue authorization 
under mutual recognition, the dossier is referred for decision to an ECHA coordina-
tion group, comprised of representatives of MS CAs, which must reach a decision 
within 60 days. If this fails, the final arbiter is the Commission.
In practice, it is rare indeed for any of these required time-scales to be achieved 
by the Commission and MS CAs. It is equally rare for a cMS to issue an authoriza-
tion by mutual recognition without recourse to the original product dossier and 
more detailed consideration of the product in question in the context of national 
priorities. Therefore, once again, a key purpose of the BPR is not achieved. Indeed, 
far from resulting in harmonized product use patterns and product labels across the 
EU, the implementation of the BPR seems to have crystalized the different regula-
tory approaches, and concerns, among the countries involved. No attempt will be 
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made here to summarize the status of AR regulation in each EU MS because these 
are highly varied and constantly changing, but here are a few examples:
• In some countries, particularly in Germany, Holland, Belgium and Scandinavian 
MSs, second-generation anticoagulants cannot be sold to and used by amateurs 
(see Chap. 12 for definitions of user groups) – even in the small packs that have 
been previously available to them for decades. (A similar restriction has been 
recently been imposed on amateur in the US by the US EPA.) In others, particu-
larly in the UK and countries of southern Europe, such products remain available 
to amateurs because these MSs consider that effective rodenticides must be 
available to the public to protect their health and well-being. Products, pests, and 
use patterns are identical, but regulatory approaches of the MS CAs differ com-
pletely when weighing the balance between public health and environmental 
risk.
• Products containing bromadiolone have been removed from the market in the 
Netherlands after the publication of a report that resistance to this active sub-
stance occurs in some parts of the country (Meerburg et al. 2014). However, a 
survey of anticoagulant resistance among house mice in Germany (Pelz et al. 
2012) has found resistance to the first-generation anticoagulants in 24 out of 25 
sites examined. In spite of this conclusive evidence of widespread resistance, the 
German CA has introduced a regulatory scheme in which only the widely- 
resisted FGARs are to be made available to amateurs for mouse control.
• Because of the widespread resistance in UK Norway rats to difenacoum and 
bromadiolone (Buckle 2013), the CA (the Health and Safety Executive) has just 
removed a 30-year-old ban on the use of resistance-breaking products based on 
brodifacoum and flocoumafen outside buildings; thus, permitting them to be 
used for the first time for the control of rat infestations. However, the regulatory 
authorities of several Nordic countries are now introducing just such a ban on the 
use of these products outdoors.
• The most common pattern of use of all ARs in the EU is “in and around build-
ings,” and there is a sensible definition of this pattern of use provided by the EC 
(European Commission 2009), which permits AR application wherever rats 
infesting buildings are found to live, both indoors and out. However, this has not 
prevented MSs from ignoring this definition and introducing their own. For 
example, in Spain, AR application ‘around’ a building is permitted only up to 
2 m from the walls of the building. Thus, control action cannot be taken at the 
site of infestations and, instead, practitioners are permitted to apply bait only 
within 2 m of the facility to which they are trying to prevent rodent ingress.
The European Commission attempted to reassert harmony into this disparity by 
employing a group of EU government and academic experts to assess and report on 
effective and proportionate risk mitigation measures for ARs (Berny et al. 2014). 
However, there is little sign that this initiative has had any effect on the differing 
regulatory perspectives of the EU MS CAs to the ARs.
The processes of implementation of the BPR are described in more detail on the 
website of ECHA (http://echa.europa.eu/). There is also a particularly useful series 
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of web-pages at the website of the UK CA, the Health and Safety Executive (http://
www.hse.gov.uk/biocides/index.htm).
4.3  Consequences of the BPD/BPR and Streamlining
There is little doubt that the implementation of the BPD and BPR has placed a mas-
sive strain on the regulatory resources of the European MSs. Staff members of MS 
CAs have to take on an additional workload and travel to cover European responsi-
bilities in addition to ongoing national duties. However, an initial lack of resources 
within the CAs of many (if not all) EU MSs, only now slowly being remedied, has 
resulted in implementation time-tables for the BPD, and latterly the BPR, being set 
back on numerous occasions. The time-table for BPR implementation is now run-
ning about 10 years behind that originally envisaged.
Two novel procedures have been implemented to streamline the process and to 
save the resources of regulators and manufacturers alike. The first is a process called 
‘Union Authorisation’ (UA). This is now intended to provide an element of harmo-
nization that has not been delivered by the process of mutual recognition. To achieve 
a UA, an applicant must again engage first with an rMS designated by 
ECHA. However, the procedure of mutual recognition (i.e., national recognition of 
the rMS authorization by other MSs) is replaced by Union-wide authorization 
granted by ECHA and the European Commission. The mechanism used by ECHA 
for granting UAs is through the BPC and similar to the one applied for active sub-
stances (see above). This approach is generally welcomed by manufacturers, 
although national CAs are wary of it, as they lose the power to determine what 
biocides are used in their territories.
A second attempt at streamlining is provided by the ‘Biocidal Product Family’ 
(BPF) concept. In this, a manufacturer submits a dossier of information and obtains 
an authorization for a ‘frame formulation’. This is a generalized formulation con-
taining a series of specified components, which may itself never be sold. Several, or 
indeed many products, can then be put on the market under the initial authorization 
as long as data is provided to show any variations from the frame formulation meet 
specified narrow guidelines with respect to any differences, and present risks that 
are lower than those of the frame formulation itself. Once again, this innovation is 
welcomed by manufacturers but it remains to be seen if its implementation by MS 
CAs will meet its objectives of reducing regulatory workload and providing 
enhanced protection of human health and the environment.
A series of studies of the impacts of these regulatory instruments on the avail-
ability of biocidal products and on product innovation has been carried out both by 
the Commission and by industry. The most recent, conducted by the International 
Association for Soaps, Detergents and Maintenance Products (A.I.S.E.) and the 
European Biocidal Products Forum of the Confederation of European Chemical 
Manufacturers (Cefic), has shown that a predicted 25% of all existing biocidal prod-
ucts will leave the market in the coming years (AISE/EBPF 2015).
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Although it is impossible to quantify, the effect of these regulations on industry 
innovation has been considerable. Budgets that would have been committed to the 
development of novel active substances and new biocidal products have instead 
been spent to keep existing products on the market (AISE/EBPF 2015). The stated 
objectives of the BPD/BPR are laudable, namely the harmonization of biocidal 
product authorization across the countries of the EU and, thereby, the enhanced 
protection of human health and the environment. However, 17 years after the publi-
cation of the BPD, and with vast resources of time and money already expended, it 
is can be said, with reasonable confidence, that these objectives are far from being 
fully achieved.
4.4  Decision of the ECHA Risk Assessment Committee on ARs
A recent decision made by ECHA’s Risk Assessment Committee (RAC) looks set to 
alter radically the regulatory landscape for ARs in the EU. RAC has decided to clas-
sify all ARs as “toxic to reproduction” (European Commission 2016b). This deci-
sion has been made on the basis that all ARs are analogous to warfarin, a known 
teratogen, and in spite the fact that toxicological studies on all other ARs show little 
evidence of teratology. Nevertheless, a Specific Concentration Limit (SCL) has 
been set at 30 ppm for all AR active substances, and products containing them at 
greater concentrations must carry an appropriate label statement. EU regulation pre-
vents any products so labelled from being sold to, and used by, amateurs and, at 
first, this was thought to be the main regulatory effect. However, further consider-
ation has found that some professionals may not wish to use these products, and 
their customers may not want them deployed on their premises, especially where 
there is general public access. It seems likely, therefore, that there will be a shift 
from 50 ppm to <30 ppm concentration in many SGAR products, with possible 
effects on product efficacy and resistance development. Effective FGAR products 
are implausible with active ingredient concentrations <30 ppm, and the place of this 
group of substances in the EU rodenticides market seems increasingly tenuous.
4.5  The Plant Protection Products Directive and Regulation
The general statement that rodent depredations of growing crops in the EU are sel-
dom of great financial consequence is undoubtedly true (Buckle and Pelz 2015), 
although this is no consolation to those farmers and growers who occasionally do, 
indeed, sustain severe damage to their valuable crops and produce. In particular, 
damage to grassland and fodder in some parts of eastern France and Switzerland 
may be catastrophic during the periodic cyclical fluctuations of some vole species. 
Severe damage is also reported in young forestry plantations in the countries of 
Fennoscandia and in fruit orchards across continental Europe. There are also 
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cyclical outbreaks of damage by voles to fruit, cereal and fodder crops across 
Europe, from Portugal in the west to the countries of the former Yugoslavia in the 
east.
The use of rodenticides for crop protection, however, brings risks in addition to 
those presented by rodenticides used as biocides. In particular, when ARs are 
applied for the protection of broad-acre, orchard and forestry crops, risks to wildlife 
and the wider environment, particularly potential contamination of soil and water, 
are of special concern. This is because crop protection application methods do not 
confine rodenticides to protected bait stations and rodenticide baits that are not con-
sumed by target rodents cannot easily be retrieved (see Chaps. 2 and 12). 
Furthermore, it is axiomatic that populations of a wide range of wildlife species are 
likely to be greater in areas of agriculture and horticulture than in urban and sub- 
urban environments. Consequently, the suite of regulatory chemistry, toxicology 
and environmental studies required to quantify the risks for AR applications for 
crop protection is proportionately increased. This additional regulatory burden, as 
well as our current knowledge of the risks of the ARs (the subject of this book), has 
resulted in fewer applications of rodenticide active substance approvals, and prod-
uct authorizations, under the PPPD/PPPR. Indeed, among ARs the only active sub-
stances approved for use in plant protection in the EU are chlorophacinone, 
difenacoum, and bromadiolone. We must presume that it was an active decision by 
manufacturers not to pursue crop protection authorizations of the three most potent 
ARs, brodifacoum, difethialone, and flocoumafen.
The processes of active substance approval and product authorization for roden-
ticides through the PPPR are similar to those already described for the BPR and will 
not be further discussed. However, the MS CAs that assess crop protection AR uses 
are often different to those employed for biocides. For the former, MS departments 
and ministries of agriculture usually provide CA representation, whereas for bio-
cides, representatives generally come from ministries of health.
4.6  Possible Effects of ‘Brexit’
At the time of writing, little is known of the precise nature of the cessation of mem-
bership of the EU by the UK (‘Brexit’) and how it will be implemented. What fol-
lows is, therefore, speculative. However, Brexit seems unlikely to have a profound 
effect on the way that ARs are regulated in the UK. Obviously, UK manufacturers 
wishing to export rodenticide products into the EU will remain bound by its rules. 
Classification, labelling and packaging is overseen the ECHA Risk Assessment 
Committee (RAC) and, while no longer bound to do so, the UK Competent Authority 
for biocides (HSE) would have to have very firm scientific grounds to deviate sig-
nificantly from decisions made by that body. In terms of the more practical aspects 
of AR use, such as who may use these products and where they may be applied, 
there has been such disagreement among EU Member States (see above) that the 
principle of harmonization, fundamental to the EU policy of free movement of 
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goods, has been partially set aside in the case of products containing the ARs. HSE 
is therefore likely to continue its current regulatory policies on the sale and use of 
ARs in the UK for the foreseeable future.
5  Regulation of Anticoagulant Rodenticides in Australia
5.1  Rodenticides: Past
The evolution of rodenticide regulation in Australia is not unlike what occurred in 
the US since the 1940’s with initial and current legislation enacted to ensure 
agricultural- focused uses were effective and safe for consumers. In Australia, all 
rodenticides, irrespective of use pattern, are considered agricultural chemicals as 
defined in the AgVet Code, which is a schedule to the Agricultural and Veterinary 
Chemicals Code Act 1994 (www.comlaw.gov.au/Series/C2004A04723”\t”_blank”). 
Pre-1950, rodenticides were non-selective acute poisons like strychnine, arsenic, 
phosphorous, and thallium sulphate. After the second-world-war, sodium monoflu-
roacetate, organochlorines, and organophosphates were also approved for agricul-
tural crop protection (Ryan and Jones 1972). From 1970 to 1980, the reactive 
emergency-use of acutely toxic chemicals were without exception permitted, coor-
dinated and managed by state government agencies and gradually fewer of these 
classes of chemicals were used for the manufacture of poison laced grain until only 
strychnine remained. Just as in the US, during the 1980s, progressive restrictions 
around pesticide use increased. By 1996, emergency use of strychnine as an in-crop 
rodenticide ceased altogether. This coincided with the approval of zinc phosphide as 
a rodenticide and a commercially manufactured ready-to-use laced grain product in 
1997. Zinc phosphide remains, to this day, the only approved rodenticide active for 
in-crop or in-field agricultural applications not requiring bait stations, but it is not 
approved for commensal rodent control. Coumatetralyl (SGAR) has limited in-field 
uses for sugarcane, macadamias and pineapples, in bait stations.
The availability of ARs for commensal rodent control around homes and other 
built environs and infrastructure resulted in this class of rodenticides rapidly over-
taking the use of acute poisons on a volume basis. Their original and currently 
approved use patterns made them readily accessible to the general public, and over 
time this has increased the risk of human exposure and non-target hazards, which 
has led to a commensurate increase in federal and state/territory government legisla-
tion and regulation aimed at mitigating human exposure risks and to a lesser extent 
environmental toxicity risks.
Legislation and regulation controlling the approval and use of pesticides in 
Australia was up until 1993 enacted and set by six independent states and two ter-
ritories. This legislative and regulatory duplication exists because each state was 
formed as and remained a partly self-governing British colony up until 1901, after 
which they agreed to Federate and become states of a single nation, Australia. 
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During federation, Australia’s national constitution and federal government were 
adopted, and the power conferred to the Commonwealth federal government did not 
extend to the approval of what chemicals could be used, nor how chemicals could 
be used in the states and territories.
5.2  Rodenticides: Contemporary Times
Almost 100 years later, Australia’s state and territory governments identified the 
need to improve the registration process and labelling of agricultural and veterinary 
chemicals with a view to (1) achieving national uniformity in the registration and 
approval of chemical supply and use, and (2) establishing a mechanism for system-
atically reviewing chemicals authorized for sale and use under existing state and 
territory-based registration schemes.
As a result, in 1991 the Commonwealth, states and territories agreed to establish 
the National Registration Scheme (NRS) for agricultural and veterinary chemicals. 
The creation of the NRS was enabled through the Agricultural and Veterinary 
Chemicals Act 1988 (www.legislation.gov.au/Details/C2004A03684) and sought to 
place under one national umbrella the assessment and registration of all Agvet 
chemical products. The NRS was operated by the National Registration Authority 
(NRA) created in 1993 under the Agricultural and Veterinary Chemicals 
(Administration) Act 1992 (http://www.austlii.edu.au/au/legis/cth/consol_act/
aavca1992511/) as an independent statutory authority. The NRA was responsible 
for the implementation of the Agvet Codes that are schedules to the Agricultural and 
Veterinary Chemicals Code Act 1994. These detailed the provisions allowing the 
NRA to evaluate, approve/register and review active constituents and agricultural 
and veterinary chemical products (and their associated labels); to issue permits and 
to license the manufacture of veterinary chemical products. It also contains provi-
sions for controls to regulate the supply of chemical products; and provisions ensur-
ing compliance with, and for the enforcement of, the code. Although the national 
regulator was and is responsible for chemical and product approvals, their legisla-
tive reach extended only to the point of sale of pesticide products. Once rodenticide 
products were in the hands of end-users, which depending on scheduling may 
require supply via Australian state or territory agency employees, it was the respon-
sibility of the state/territory governments to ensure compliance to the control of use 
regulations in each state/territory. This is arguably to the detriment of product effec-
tiveness given the control of use regulations are not consistent between Australian 
states and territories, which is a situation mirrored in the US and between EU mem-
ber states.
The Australian regulatory authority changed its name in 2003 to the Australian 
Pesticides and Veterinary Medicines Authority (APVMA). The reasoning for the 
name change was two-fold: firstly, it was inconsistent with international nomencla-
ture practised by other international chemical regulators within the Organization for 
Economic Cooperation and Development (OECD), which sets the international 
11 An International Perspective on the Regulation of Rodenticides
312
standards and benchmarks for chemicals management, and secondly, and somewhat 
humorously, a survey in 1998/99 highlighted the acronym was often confused with 
the National Rifle Association in the US.
The APVMA was now, like the US EPA, responsible for all agricultural chemical 
active ingredient and product approvals, which currently number, 2687 and 8446 
respectively. Of the 8446 approved products, 166 are rodenticides (all classes), 135 
are SGARs, 13 are FGARs and 18 are others (e.g., zinc phosphide, alphachloralose, 
cholecalciferol (Table 11.3) . From the inception of the Australian regulator to the 
present day, the approval process for new products or labels standardizes all chemi-
cal assessments, labelling and packaging by requiring a consistent package of data 
and taking into account proposed product use as stated on the label.
In addition, the application assessment process involves allocating a ‘Schedule’ 
to a new agricultural chemicals and products based on their overall hazard, taking 
into account information about their toxicology, environmental toxicity and pro-
posed use. Scheduling of chemicals and products is the responsibility of the 
Australian Committee for Chemicals Scheduling (ACCS) who use the Standard for 
the Uniform Scheduling of Medicines and Poisons (SUSMP)  (www.legislation.
gov.au/Details/F2016L00849), which takes its legislative imprimatur from the 
Therapeutic Goods Act 1989. There are 10 Schedules that are applied to all agricul-
tural and veterinary chemicals and products. Acutely toxic rodenticides (e.g., zinc 
phosphide baits and fumigant products) have all been allocated a Schedule 7. 
SGARs and FGARs are in the main allocated a Schedule 6, but there are nine prod-
ucts containing either warfarin or coumatetralyl that have been allocated to Schedule 
5 (Table 11.4) .
As occurs in the EU and the US, the APVMA has powers under sections 31 to 34 
of the Agricultural and Veterinary Chemicals Code Act 1994 to conduct reviews of 
registered chemicals. In broad terms, these powers include the authority to recon-
sider the approvals of active constituents and the registration of products and their 
labels, and to require registrants to provide information that may not have been 
required for the assessment of original product registrations.
In February 2016, the active constituents: brodifacoum, bromadiolone, difena-
coum, difethialone, and flocoumafen were placed on a priority list for  reconsideration. 
Table 11.3 Scheduling of rodenticide products according to the Standard for the Uniform 
Scheduling of Medicines and Poisons (SUSMP) (Gill 2016)
Schedule 5. Caution – Substances with a low potential for causing harm, the extent of which 
can be reduced through the use of appropriate packaging with simple warnings  
and safety directions on the label.
Schedule 6. Poison – Substances with a moderate potential for causing harm, the extent of 
which can be reduced through the use of distinctive packaging with strong 
warnings and safety directions on the label.
Schedule 7. Dangerous Poison – Substances with a high potential for causing harm at low 
exposure and which require special precautions during manufacture, handling  
or use. These poisons should be available only to specialised or authorised  
users who have the skills necessary to handle them safely. Special regulations 
restricting their availability, possession, storage or use may apply.
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Scoping of the reconsideration is to commence in December 2016, with the recon-
sideration to commence at a later date taking into account relevant, new scientific 
information available since their original approvals with the following facts taken 
into account in the prioritization decision:
• These chemicals persist in organs of poisoned rodents and present a risk to non- 
target animals that feed on poisoned animals or carcasses.
• Use of products in domestic premises, animal production facilities and food pro-
duction facilities is currently allowed. This presents potential risks to humans, 
pets and wildlife through accidental poisoning. Around 1400 human exposure 
incidents to rodent baits are reported to Poisons Information Centres annually.
• Products are not intended for use in crops or the field, though some labels make 
it difficult to discern this.
• Use of liquid formulations are a concern because they are not designed for use in 
bait stations.
Fortunately, the registration reconsideration process does take into account the 
downside risks and in this case the APVMA has pragmatically identified that remov-
ing SGARs carries with it the risk that less effective anticoagulants will be the only 
option for controlling rodents in commensal situations. The registration reconsid-
eration process that began in February 2016 for these SGARs is not yet complete, 
so the implications for SGAR regulation in Australia remains to be seen.
6  Conclusion
Rodents inflict damage to growing crops, grasslands, orchards, and fodder (Buckle 
and Pelz 2015); foodstuffs by direct consumption and contamination during stor-
age, production, transport and sale; physical damage to property, installations and 
belongings; and perhaps of greatest importance, the transmission of diseases to 
Table 11.4 Rodenticide 
active ingredients and 
number of rodenticide 
products currently by the 
APVMA in Australia
Active constituent
Number of Approved 
Products
Brodifacoum SGARa 62
Bromadiolone SGAR 33
Coumatetralyl SGAR 6
Difenacoum SGAR 37
Difethialone SGAR 10
Diphacinone FGARb 1
Flocoumafen SGAR 5
Warfarin FGAR 6
Total 160
aSecond Generation Anticoagulant Rodenticide
bFirst Generation Anticoagulant Rodenticide
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humans and domesticated animals (see Chap. 1). Rodenticides, by design, are 
lethally toxic, and in most situations this toxicity pathway is not unique to rodents. 
Consequently, their use presents a risk to humans and the environment and mea-
sures must be taken to lessen the potential risk. Traditionally, and perhaps as it 
should be, that responsibility falls to government entities. Government officials, in 
turn, use the most basic available tool to them: enacting regulations and implemen-
tation procedures. Like most product-driven markets, regulations typically impose 
manufacturing and labeling standards on manufacturers, but regulations and risk 
mitigation measures are also aimed at the end-user of the products. Ultimately, 
proper use, stewardship, and training on the safe use of pesticide products are the 
responsibility of the end-user.
This chapter has presented four examples on the development of pesticide regu-
lation in international markets. In each example, the country or collection of coun-
tries (EU) followed their own unique path toward current regulatory paradigms, but 
ended at essentially the same point, a focus on product performance, and safety to 
humans and the environment. In all four regulatory environments, AR use is still 
allowed, but they are under increasing scrutiny as a result of growing public concern 
and regulatory response to that concern, some of which is justified. However, the 
conclusions international regulators are making on the risk and benefits of contin-
ued product use and the disparate policies they are adopting, have created an inter-
national regulatory environment that is difficult and costly for product manufactures 
to navigate. Harmonization of world pesticide regulation standards would serve to 
rectify this disparity, but agreement may be extremely difficult, as is being wit-
nessed by the EU harmonization effort.
As was observed in the case of strychnine in the US, the disappearance of prod-
ucts did not occur overnight as a result of a sweeping legislative actions. It took 
40 years of study, growing public concern, an executive-level ban on the product, a 
series of judicial reviews, and the US EPA’s unwillingness to challenge judicial 
decisions, to arrive to the situation today where strychnine is a minor player in the 
rodenticide market. It is the opinion of the authors that ARs, especially SGARs, are 
experiencing similar regulatory paths. Restrictions on AR use throughout the world 
are not being driven by high level congressional, parliamentary actions, or executive 
level actions, but are succumbing to the effects of regulatory implementation and 
associated risk mitigation measures enacted by well-intentioned regulators.
In many cases, risk mitigation measures are justified for continued use ARs (see 
Chap. 12). As pointed out in other chapters of this book, there is a significant body 
of evidence that many wildlife taxa are exposed to ARs, in particular SGARs, almost 
wherever they are used. Certainly, there is also evidence that some wildlife have 
been killed by ARs. That knowledge alone might be justification enough to severely 
restrict their use or even ban them. However, no significant advances in rodenticide 
chemistry have been made since the introduction of SGARs and cholecalcifereol 
more than 30 years ago. The risks and benefits of the old chemistries we rely on are 
becoming better understood and it goes without saying that all products come with 
their own unique set of issues. Forcing a shift from ARs to other chemistries is sim-
ply substituting one set of risks for another.
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As is usually the case, more information is needed properly to evaluate the risks 
and benefits of continued AR use. Early research focused heavily on acute effects of 
exposure to rodenticide baits and residues in tissues of poisoned animals. Recent 
research trends are focused on sub-lethal exposure scenarios and the impact of low- 
level, potentially non-lethal levels of residues in the tissues of exposed animals (see 
Chap. 3). This is an area that deserves a more in depth understanding. However, it 
should also be balanced with an equal understanding of what sub-lethal exposure 
actually means in relation to the health of individual animals and their possible 
impact on the ability of species to maintain viable populations. The same can be 
said for understanding the risks of other exposure scenarios such as repeat expo-
sures and exposure to multiple ARs either concurrently or over time.
A systematic study is warranted of pesticide regulations and the associated suc-
cess or failure rate of those regulations on meeting their intended objectives. As 
pointed out above, changes in product availability provides the opportunity to 
observe the direct impact of regulations. This measure alone is not adequate if one 
tries to draw conclusions on the real impact on protection of human or environmen-
tal protection. For example, as the use of one product decreases and the use of 
another increases, questions arise around what new risks have been realized or ben-
efits have been given up. In reality, funding for this type of research is extremely 
limited. Government regulators are typically inadequately funded and there is little 
incentive for industry to conduct this research. It is essential however, that regula-
tors take informed and balanced positions, and do not act precipitately, in the 
absence of concrete information. Application of unreasonable risk mitigation could 
result in the loss of valuable products, potentially resulting in unacceptable levels of 
loss to food supplies and increased risk of negative impacts to human health and 
safety.
It is apparent that the number of years AR products will be available for opera-
tional rodent management is limited. Such is the life of any pesticide product. 
Whether it is a growing understanding of a product’s unanticipated consequences, 
target pests developing resistance to chemistries, growing public concern, or over- 
regulation, a pesticide product’s days are numbered beginning the day it is first 
registered. In the case of rodenticides, you only need to look at strychnine, red 
squill, and arsenic-based products to observe the life of a pesticide. In many 
instances, this obsolescence is warranted. As presented above, the perception of the 
risk and benefit of SGARs varies among governments. The availability of SGARs is 
likely shorter in the US than other countries. What will be the next in line in the 
evolution of rodenticides? Perhaps it will be simple reformulation of existing active 
ingredients. Will that meet future rodenticide needs into the twenty second century? 
The future more than likely lies in the development of new active ingredients, bio-
logical agents and novel technologies that have a higher degree of target species 
specificity. However, the costs necessary to bring a new active ingredient to market 
are extremely high and the time-frames very long. Risk of failure, low market 
potential and short product life, only lessens the desire or ability of a private manu-
facture to invest in such an endeavor.
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One thing is certain, the quest for new rodent management techniques, including 
rodenticides, will be never-ending. Adequate scientific understanding of the risks 
and benefits accompanying new technologies will lag behind product development 
and as a result, regulations will be reactionary as regulators address the impacts of 
new technologies. Perhaps, as is currently being attempted in the EU, governments 
will work out harmonized international regulatory standards and systems, thereby 
reducing the costs and time required to bring new safer, more effective technologies 
to market.
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